Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses
about
Understanding natural herpes simplex virus immunity to inform next-generation vaccine designMathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital MucosaPhase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected SubjectsAn indole alkaloid from a tribal folklore inhibits immediate early event in HSV-2 infected cells with therapeutic efficacy in vaginally infected miceCD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpesClinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection.Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis.Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.Gamma interferon impedes the establishment of herpes simplex virus type 1 latent infection but has no impact on its maintenance or reactivation in mice.Herpes simplex virus and the chemokines that mediate the inflammation.Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.Recent progress in herpes simplex virus immunobiology and vaccine researchLack of CD4(+) T cells does not affect induction of CD8(+) T-cell immunity against Encephalitozoon cuniculi infection.Homing in on the cellular immune response to HSV-2 in humans.The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men.Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanismsProspects and perspectives for development of a vaccine against herpes simplex virus infections.Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.A mucosal vaccination approach for herpes simplex virus type 2.Persistence of mucosal T-cell responses to herpes simplex virus type 2 in the female genital tractSingle and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal modelsA Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell ImmunogensPeripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Viral modulation of T-cell receptor signalingA locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice.Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study.Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptorInteractions and management issues in HSV and HIV coinfection.CD8 T cells and latent herpes simplex virus type 1: keeping the peace in sensory ganglia.Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infectionRapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
P2860
Q26741484-1FCE6410-BACF-471E-9C54-9CEE69485FB5Q27347896-50C5A660-41EF-4E29-9AED-B4B55295CB25Q27486108-9AD602EB-779C-4D4A-9373-1BF06E3DCC8CQ28534570-28F36C61-F56D-4ECC-A8C9-518F8FECFC7CQ30957753-C0786176-0398-4698-928F-20BDB90B9450Q33248961-1B23F85A-C5B0-494B-80B6-3602FA501927Q33550768-1BB8B0CB-DDAE-4CFA-8BDD-A37784A43670Q33625030-32989311-A73E-47E8-BDC9-EB0563C05EE0Q33653142-BD9CEAF2-FD8C-46D6-B8E5-A3EB113C3EB5Q33782022-A7EC09E5-8AF3-4991-B9DD-A116D777874FQ33785966-0361B4F8-4C74-40D6-A58A-B2AD9E2EDD54Q33808288-B8361678-6AF5-4ED3-8033-3475C091AEDFQ33825406-B419F709-9020-4767-9065-55DA0F00BC38Q33826410-01808061-CE34-4A73-9FA2-F6ED3D114FEAQ33881052-C6A168A5-67DE-477A-9C23-B82DCABC1478Q33963713-2794E17A-9E59-4D4B-914F-38D2FD98624BQ34004978-2B3B6789-BD89-4F8F-85E3-519218874CCBQ34081670-F2805833-9FA2-41D3-992B-9B2592235071Q34142034-148B90C2-EF5B-425C-9864-13B5BC661EB1Q34142890-AB53F457-F626-4DD5-8788-96C11D9FA715Q34431547-3B6F1F62-62F4-4F8F-8DA8-C3437AA5410AQ34529742-817331AB-18B8-40AD-9E03-94F4BCCDA396Q34558350-BE08E434-D719-4F2E-A018-41F3ED2D721DQ34681733-28FBD280-8765-4DA1-8982-A4447A20DEE1Q35271194-E35F2C2F-C0A1-4496-AC24-C45878B785A4Q35914367-8DBA9D4F-AF20-443A-8A1E-8E5B4B2E7845Q36246306-25B24EC3-A8B4-4E85-9C9A-6739CAD55EC6Q36267182-BD490B63-087A-4CB5-A356-D63C288B0726Q36339059-BA33F78A-6DC1-4413-8A89-6A4CCDD8ABC4Q36520832-DEABBD11-3ED1-40DE-BF5C-78117C91843AQ36540182-1DC48555-ECEE-4BCA-8E0A-1A6A5BB8D1BCQ36540912-303795E0-1249-49CD-B5FF-15C5577BD0E7Q36555158-D0323819-FBA4-4FFB-9407-86DD71F24183Q36562841-FB9B8C68-9E06-4A19-8C03-DC740703921AQ36689912-90B0285B-042D-4BDA-A505-308B4CA98A88Q36777844-058730D4-146B-49B1-B575-BFD7D0752400Q36922242-DF7211A0-C959-4FE2-B15C-54CC12100428Q36974311-FE39E67F-8DD3-4F63-8195-D04068651406Q37174520-83F45AD3-F2B7-40EA-ABB4-7CD10F839209Q37335794-04378D3C-9185-45B2-A440-8107CD691416
P2860
Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@ast
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@en
type
label
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@ast
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@en
prefLabel
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@ast
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@en
P2093
P2860
P356
P1476
Severe genital herpes infectio ...... totoxic T lymphocyte responses
@en
P2093
C M Posavad
M F Shaughnessy
P2860
P304
10289-10294
P356
10.1073/PNAS.94.19.10289
P407
P577
1997-09-01T00:00:00Z